Thermo Fisher Scientific Inc. (TMO) Shares Sold by BB&T Securities LLC

BB&T Securities LLC decreased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 77,845 shares of the medical research company’s stock after selling 2,822 shares during the quarter. BB&T Securities LLC’s holdings in Thermo Fisher Scientific were worth $17,421,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in TMO. Vanguard Group Inc. boosted its position in Thermo Fisher Scientific by 1.2% during the third quarter. Vanguard Group Inc. now owns 29,271,095 shares of the medical research company’s stock worth $7,144,489,000 after acquiring an additional 347,836 shares during the last quarter. Vanguard Group Inc boosted its position in Thermo Fisher Scientific by 1.2% during the third quarter. Vanguard Group Inc now owns 29,271,095 shares of the medical research company’s stock worth $7,144,489,000 after acquiring an additional 347,836 shares during the last quarter. BlackRock Inc. boosted its position in Thermo Fisher Scientific by 0.9% during the third quarter. BlackRock Inc. now owns 25,233,243 shares of the medical research company’s stock worth $6,158,932,000 after acquiring an additional 226,824 shares during the last quarter. Capital World Investors boosted its position in Thermo Fisher Scientific by 19.2% during the third quarter. Capital World Investors now owns 15,412,242 shares of the medical research company’s stock worth $3,761,820,000 after acquiring an additional 2,482,783 shares during the last quarter. Finally, FMR LLC boosted its position in Thermo Fisher Scientific by 18.5% during the third quarter. FMR LLC now owns 6,499,139 shares of the medical research company’s stock worth $1,586,310,000 after acquiring an additional 1,016,082 shares during the last quarter. Institutional investors and hedge funds own 91.80% of the company’s stock.

TMO opened at $247.39 on Thursday. The stock has a market cap of $100.12 billion, a P/E ratio of 22.25, a price-to-earnings-growth ratio of 1.60 and a beta of 1.14. Thermo Fisher Scientific Inc. has a twelve month low of $199.85 and a twelve month high of $253.91. The company has a current ratio of 1.71, a quick ratio of 1.23 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, January 30th. The medical research company reported $3.25 earnings per share for the quarter, topping analysts’ consensus estimates of $3.19 by $0.06. The firm had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.26 billion. Thermo Fisher Scientific had a net margin of 12.06% and a return on equity of 16.86%. Thermo Fisher Scientific’s quarterly revenue was up 7.6% on a year-over-year basis. During the same period in the previous year, the business posted $2.79 earnings per share. Equities analysts predict that Thermo Fisher Scientific Inc. will post 12.14 EPS for the current year.

In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 9,500 shares of Thermo Fisher Scientific stock in a transaction dated Friday, December 7th. The shares were sold at an average price of $241.45, for a total transaction of $2,293,775.00. Following the transaction, the chief financial officer now directly owns 44,124 shares of the company’s stock, valued at $10,653,739.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Gregory J. Herrema sold 17,235 shares of Thermo Fisher Scientific stock in a transaction dated Thursday, November 29th. The stock was sold at an average price of $247.00, for a total transaction of $4,257,045.00. Following the transaction, the insider now directly owns 26,446 shares in the company, valued at $6,532,162. The disclosure for this sale can be found here. Insiders have sold 32,607 shares of company stock worth $7,972,085 over the last 90 days. 0.49% of the stock is currently owned by company insiders.

A number of research firms recently weighed in on TMO. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $256.00 price target on the stock in a research report on Wednesday, December 19th. Robert W. Baird boosted their price target on shares of Thermo Fisher Scientific from $256.00 to $264.00 and gave the stock an “outperform” rating in a research report on Thursday, October 25th. Three research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Thermo Fisher Scientific presently has an average rating of “Buy” and an average target price of $275.10.

TRADEMARK VIOLATION NOTICE: This news story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2019/02/14/thermo-fisher-scientific-inc-tmo-shares-sold-by-bbt-securities-llc.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

See Also: Do Tariffs Work?

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply